Purpose Prize

Marc Freedman Portrait

The Latest from CoGenerate

Got a Digital Illustration that Shows Generations Working Together?

Got a Digital Illustration that Shows Generations Working Together?

CoGenerate recently teamed up with Fine Acts, a global creative studio for social impact, to launch an open call for illustrations showing generations working together for change.  We’re looking for illustrations that show older and younger people coming together to...

A New Conversation About Service That Crosses Generations

A New Conversation About Service That Crosses Generations

Can a single meal begin to bridge divides? Back in January, two major partners in CoGenerate’s work teamed up to find out. On the MLK Day of Service, Generations Over Dinner and AmeriCorps joined with senior living communities across the country to host more than 100...


Daniel Luhata Shungu

United Front Against Riverblindness
Purpose Prize Fellow 2010

Shungu is working to purge onchocerciasis, a leading infectious cause of blindness, in the Democratic Republic of Congo through community-based distribution of medicine.

After a career with drug manufacturer Merck & Co., Daniel Luhata Shungu retired in 2002 to focus on eradicating onchocerciasis – also known as “river blindness” – a parasitic disease associated with irreversible blindness, severe itching, reduced life span, lizard-like skin and serious socioeconomic problems.

Seven million people are infected and approximately 70,000 are already blind or visually impaired in Shungu’s native Democratic Republic of Congo, where he is focusing his work. Once a person becomes blind, he or she becomes dependent on family members, especially children, who end up forgoing school to tend to their blind relatives.

Through training, capacity building and community empowerment, Shungu’s Lawrenceville, N.J.-based organization, United Front Against Riverblindness, is putting free medicine in the hands of local communities through designated community distributors who administer the drugs annually over a 10-year period to those affected. The distributors take personal responsibility for the success of the treatment and are in turn highly respected and recognized with gifts from their communities.

Nearly 1 million doses have been distributed so far. Early distribution success has encouraged Shungu to expand the efforts into new regions. Of his work, he says: “The satisfaction of realizing that the lives of many of the much less fortunate and previously helpless people in remote parts of Africa are being changed for the better is very hard to describe.”